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Breast cancer incidence and mortality in a
transitioning Chinese population: current and
future trends
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1School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China and 2City
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Background: Projections of future trends in cancer incidence and mortality are important for public health planning.
Methods: By using 1976–2010 data in Hong Kong, we fitted Poisson age-period-cohort models and made projections for future
breast cancer incidence and mortality to 2025.
Results: Age-standardised breast cancer incidence (/mortality) is projected to increase (/decline) from 56.7 (/9.3) in 2011–2015 to
62.5 (/8.6) per 100 000 women in 2021–2025.
Conclusions: The incidence pattern may relate to Hong Kong’s socio-economic developmental history, while falling mortality
trends are, most likely, due to improvements in survival from treatment advancement and improved health service delivery.
Breast cancer is the most common malignancy and the leading
cause of cancer-related death in women, accounting for 10% of
new malignancies worldwide annually, andB22% of malignancies
among women (Ferlay et al, 2004). In Hong Kong (HK) the most
westernised and urbanised city in China, breast cancer is the most
common cancer and the third leading cause of cancer-related
mortality among women (Cancer Statistics, 2013). There are clear
differences between populations in the East and the West in terms
of breast cancer incidence and mortality (Figure 1), the precise
aetiology of which remains unclear.
Age-period-cohort (APC) models allowing examination of trends
in disease rates over time (Holford, 1991, 1992) have long been
deployed to further understanding of the biologic and environmental
causes of cancer (Holford, 1991, 1992). By using APC methods, we
estimated the relative contribution of effects from age, period and
birth cohort to trends in breast cancer incidence and mortality, and
projected future trends to the medium term.
MATERIALS AND METHODS
We obtained age-specific breast cancer incidence, death data
(defined according to the International Classification of Diseases
(ICD) codes as ICD-8 174, ICD-9 174 and ICD-10 C50, C50.0–
C50.9) and mid-year population figures for the years 1976–2010
from the HK Cancer Registry (2013), the Death Registry and the
Census and Statistics Department, respectively. We calculated the
age-standardised incidence and mortality rates in HK according to
the World Standard Population in 2000. Non-linearities in trends
of varying time periods were characterised using segmented annual
percent change from segmented regression (Clegg et al, 2009) or
join-point regression analysis (Kim et al, 2000).
We modelled breast cancer incidence and mortality using APC
models (details in Supplementary Information 1) (Clayton and
Schifflers, 1987; Holford, 1991, 1992). We grouped the mortality/
incidence and population data into fourteen 5-year age groups
from 20–24 years to 85 or above, and seven 5-year periods from
1976–1980 to 2006–2010. This classification resulted in 20 birth
cohorts centred at 5-year intervals beginning in the 1890s. The
second and the penultimate periods and the central birth cohort
were defined as reference groups to generate identifiable estimates.
We used Bayesian inference to estimate the model parameters
(Bray et al, 2000; Bray, 2002; Brennan and Bray, 2002; Baker and
Bray, 2005). We used the resulting models to project age-
standardised breast cancer incidence and mortality rates to
medium term (until 2021–2025), with 95% projection intervals.
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RESULTS
The trends in age-standardised breast cancer incidence and
mortality rates by 5-year periods from 1976 and 2010 are shown
in Figure 2 and Supplementary Table 1. The fourth period centred
at 1993 was marked by a join-point at which the slope changed
significantly for incidence and mortality trends in 1976–2010.
The estimated parameters for the age, period and cohort
components for incidence (upper panels) and mortality (lower
panels) models are shown in Figure 3. Due to the well-known
identifiability problem of APC models, where the effects of the
three components are linearly dependent, only second-order
changes (i.e., inflection points) are interpretable. Figure 3 shows
clear second-order changes are visible for both the age effects and
the cohort effects for incidence and mortality with negligible
second-order changes in period effects. Downward inflections in
the age-specific breast cancer rates occurred at around 45–50 years
for incidence and 65–70 years for mortality. The first two inflection
points for the cohort curves have similar downturns around 1910
and upturns around 1930 for both incidence and mortality, but the
third inflection points differ, with a downturn around 1960 for
incidence and around 1950 for mortality.
Age-standardised incidence rate rose on average 1.69% per
annum in the three decades between 1976 and 2010. On the basis
of these trends, we predicted that age-standardised breast cancer
incidence rates would increase from 56.7 cases in 2011–2015 to
62.5 per 100 000 women in 2021–2025. In contrast, age-standardised
mortality rates decreased on average 0.02% per year between
1976 and 2010. The rate is projected to decline from 9.3 deaths in
2011–2015 to 8.6 deaths per 100 000 women in 2021–2025.
Disparities in the disease rates by age group were observed
(Supplementary Figure 1). Incidence is projected to increase into
the near future for womenX55 years, while mortality is projected
to decline for women agedo65 years but increase for women aged
X65 years.
DISCUSSION
We predict that age-standardised breast cancer incidence in HK
will continue to increase at a rate of 0.65% per annum, while
age-standardised mortality will decrease at 0.56% per annum over
the next 15 years. Cumulatively, this represents a projected increase
of 10.2% in incidence and a decrease of 7.5% in mortality rates
during 2010–2025. Similar to our previous findings (Wong et al,
2007), the rising incidence trends seem to have been driven mainly
by ageing and cohort effects, with no clear trends by calendar time
period. On the other hand, we observed that the overall mortality
trends appeared to be relatively stagnant over the last three
decades. Given that HK does not operate a mass mammographic
screening and only the low levels of mammography screening in
our population occur (Leung et al, 2008), these trends could be
most likely attributed to improvements in survival including
advances in treatment care such as use of Paclitaxel from the 1990s
and adjuvant hormonal (Early Breast Cancer Trialists’
Collaborative Group, 2005; Gibson et al, 2009; Burstein et al,
2010; Cuzick et al, 2010) from the 1970s and targeted
immunotherapy (Slamon et al, 2001; Madarnas et al, 2008; Costa
et al, 2010) in the 2000s, or a different case-mix. We expect
mortality to continue to decrease in the future. These findings
might also serve as a reliable epidemiological sentinel for the rest of
developing China.
Similar notable birth cohort effects occurred for both breast
cancer incidence and mortality in the first half of the 20th century.
Here, we attempt to interpret the cohort-driven trends and to
generate hypotheses based on the relevance of social history in the
evolution of population disease risk, in addition to from the
perspective of well-known contemporaneous determinants such as
lifestyle factors. Deceleration for the 1910s birth cohorts may be an
artefact of HK’s migration history. Acceleration for the 1930s birth
cohorts coincided with the first cohort of women who by migrating
from China to HK in 1945–1955 were the first generation to reach
maturity in comparatively developed HK, where gross domestic
product per head in 1951 was about five times higher than in
China (Maddison, 2001). The deceleration for the birth cohorts a
generation later around 1960 could represent an upper threshold in
the population effects of transitioning to a developed society for
East Asians, despite lower fertility, delayed childbearing (Herrinton
et al, 1994; Liao et al, 2003) (Supplementary Figure 2) and
increased oral contraceptive use for women born after 1960. On
the other hand, migration studies suggest it takes several
generations for the full effects of economic transition to become
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Figure 2. Annual age-standardised female breast cancer incidence
(red line) and mortality (blue line) rates in Hong Kong from 1976 to
2010 and projected incidence and mortality (dotted lines) to 2025
with 95% credible intervals (grey area). Notes: The sAPC (annual
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line) was marked by a join-point at which the slope changed
significantly in both the incidence and mortality trends.
China Incidence
Mortality
India
Japan
Hong Kong
Po
pu
la
tio
n
Singapore
Sweden
Canada
UK
US
0 20 40 60 80 100
Age-standardised rate per 100 000 women
Figure 1. Age-standardised rates of female breast cancer incidence
and mortality for women in 2008 (Data source: GLOBCAN 2008).
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evident for female hormonal-related cancers (Herrinton et al, 1994;
Liao et al, 2003). Notably, the mortality deceleration started earlier
for generations born around 1950s, perhaps due to generational
differences in awareness and inclination to seek screening and
treatment. Conversely, if survival remains high for these women as
they get older, then this would point to the existence of an
unidentified protective factor which has counteracted the mortality
associated with changing socio-economic and demographic
patterns.
With respect to the age curves, downward inflection points in
incidence and mortality rates were around 45–50 years and 65–70
years, respectively. The downward inflection in incidence at the age
of menopause coincides with Clemmesen’s hook, which is
classically recognised in developed countries (Clemmesen, 1948).
The subsequent downward inflection in mortality may represent
the lag between incidence and mortality.
In most Caucasian populations in the developed West, increases
in breast cancer incidence have mainly occurred in women aged
Z50 years, whereas reductions have been observed in those aged
35–49 years (Hery et al, 2008). We observed similar patterns,
although only sporadic, opportunistic mammography screening
occurs with relatively low and socially patterned coverage in HK
(Leung et al, 2008).
We also projected a reduction in age-specific breast cancer
mortality rates for women aged o65 years, and a rising trend in
the rates among women X65 years in the next 15 years. When
comparing our trends with western countries, a reduction in
mortality trends has been observed in the younger age group (o50
years) in countries where screening of young women is rare
(Denmark, Finland, Netherlands, Norway, UK) but also in those
where screening is common (France, Germany, Sweden) (Autier
et al, 2010). The relatively larger reduction in younger women
involved may reflect more effective cancer treatment and better
response to treatment (Autier et al, 2010). Similarly, the breast
cancer deaths in United States and United Kingdom decreased at
ages 20–69 years in the recent decade, probably due to many
factors including increased use of hormonal and cytotoxic
treatments for both early and advanced disease and increased
awareness of breast cancer (Peto and Boreham, 2000). These same
factors could apply in the HK context. Increased mortality
projections for older women could be due to less frequent
diagnostic activity, less intensive treatment and more frequent
diagnosis of cancer at advanced stages resulting in poorer survival
(Eaker et al, 2006; Autier et al, 2010). Investigation of the
underlying reasons is needed.
There are two potential limitations in this study. First, APC
analyses are descriptive in nature and we can only speculate the
aetiologies of the changes observed. Second, we cannot quantify the
survival benefit due to progress in early detection and treatment
care in reducing disease risk in past trends, due to lack of relevant
survival data in our Chinese population. We however estimated the
complement of the mortality to incidence ratio (1 (M/I) ratio) as
a proxy indicator of 5-year relative survival of breast cancer
(Supplementary Figure 3) (Asadzadeh Vostakolaei et al, 2011). The
proxy shows improved survival from breast cancer over times, as
the curve of 1 (M/I) ratio appears to be increasing.
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Figure 3. Parameter estimates of age (black), period (blue) and cohort (red) effects from two age-period-cohort models for female incidence
(upper panels) and mortality (lower panels) trends due to breast cancer (DIC¼916.60 for incidence rate model; DIC¼737.44 for mortality rate
model) with projections (shaded area). Leftmost upper panel (A): Estimated age-specific annual female incidence rates due to breast cancer in 5-
year age groups in Hong Kong with 95% credible intervals. Middle and rightmost upper panel (B, C): Estimated relative risks for 10-year birth
cohort (beginning in the calendar year 1889) and 5-year calendar period (beginning from 1976) effects associated with the incidence cases with
95% credible intervals, including projected cohort effects for birth cohorts centred on the years 1993, 1998 and 2003 (shaded areas) and projected
period effects for periods centred on the years 2013, 2018, 2023 (shaded area). Leftmost lower panel (D): Estimated age-specific annual female
mortality rates due to breast cancer in 5-year age groups in Hong Kong with 95% credible intervals. Middle and rightmost lower panels (E, F):
Estimated relative risks for 10-year birth cohort (beginning in the calendar year 1889) and 5-year calendar period (beginning from 1976) effects
associated with the deaths with 95% credible intervals, including projected cohort effects for birth cohorts centred on the years 1993, 1998 and
2003 (shaded area) and projected period effects for periods centred on the years 2013, 2018, 2023 (shaded area).
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